Literature DB >> 17505470

Improved retinal transduction in vivo and photoreceptor-specific transgene expression using adenovirus vectors with modified penton base.

Siobhan M Cashman1, Laura McCullough, Rajendra Kumar-Singh.   

Abstract

Adenovirus (Ad) vectors can be injected into human ocular tissues without producing adverse events and are therefore a promising means of gene transfer to the retina. However, when administered subretinally, Ad vectors primarily transduce the retinal pigment epithelium (RPE), whereas the majority of mutant gene products that cause photoreceptor (PR) degeneration are expressed exclusively in the PR cells. While it has been shown previously that pseudotyping of Ad can partially overcome the limited PR transduction by Ad5, we found that pseudotyping of Ad is not necessary for transduction of PR cells. We determined that, in the context of Ad, the cytomegalovirus (CMV) promoter is not significantly active in PRs. We compared expression levels from CMV and chicken beta actin (CBA) promoters in neural retina and found that CBA has a 173-fold greater potency than CMV. We also investigated the nature of the Ad-RPE interaction in murine retina and determined that the RGD domain in Ad penton plays a key role in RPE tropism. Deletion of the RGD domain coupled with use of the CBA promoter permitted transgene expression in neural retina approximately 667 times more efficiently than with Ad5 vectors. The use of these vectors in combination with a 4.7 kilobase (kb) rhodopsin promoter enabled transgene expression exclusively in PR cells in vivo.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17505470     DOI: 10.1038/sj.mt.6300203

Source DB:  PubMed          Journal:  Mol Ther        ISSN: 1525-0016            Impact factor:   11.454


  15 in total

Review 1.  Let There Be Light: Gene and Cell Therapy for Blindness.

Authors:  Deniz Dalkara; Olivier Goureau; Katia Marazova; José-Alain Sahel
Journal:  Hum Gene Ther       Date:  2016-02       Impact factor: 5.695

Review 2.  Gene therapy of inherited retinopathies: a long and successful road from viral vectors to patients.

Authors:  Pasqualina Colella; Alberto Auricchio
Journal:  Hum Gene Ther       Date:  2012-08       Impact factor: 5.695

Review 3.  Barriers for retinal gene therapy: separating fact from fiction.

Authors:  Rajendra Kumar-Singh
Journal:  Vision Res       Date:  2008-06-18       Impact factor: 1.886

4.  Adenovirus vectors targeting distinct cell types in the retina.

Authors:  J Harry Sweigard; Siobhan M Cashman; Rajendra Kumar-Singh
Journal:  Invest Ophthalmol Vis Sci       Date:  2009-11-05       Impact factor: 4.799

5.  Retinal Gene Therapy: Current Progress and Future Prospects.

Authors:  Cristy A Ku; Mark E Pennesi
Journal:  Expert Rev Ophthalmol       Date:  2015-04-10

6.  A non membrane-targeted human soluble CD59 attenuates choroidal neovascularization in a model of age related macular degeneration.

Authors:  Siobhan M Cashman; Kasmir Ramo; Rajendra Kumar-Singh
Journal:  PLoS One       Date:  2011-04-28       Impact factor: 3.240

7.  Soluble CD59 expressed from an adenovirus in vivo is a potent inhibitor of complement deposition on murine liver vascular endothelium.

Authors:  Jarel Gandhi; Siobhan M Cashman; Rajendra Kumar-Singh
Journal:  PLoS One       Date:  2011-06-24       Impact factor: 3.240

Review 8.  Prospects of Non-Coding Elements in Genomic DNA Based Gene Therapy.

Authors:  S P Simna; Zongchao Han
Journal:  Curr Gene Ther       Date:  2022       Impact factor: 4.676

Review 9.  Vector platforms for gene therapy of inherited retinopathies.

Authors:  Ivana Trapani; Agostina Puppo; Alberto Auricchio
Journal:  Prog Retin Eye Res       Date:  2014-08-12       Impact factor: 21.198

10.  Extended duration of transgene expression from pegylated POD nanoparticles enables attenuation of photoreceptor degeneration.

Authors:  Christina Binder; Siobhan M Cashman; Rajendra Kumar-Singh
Journal:  PLoS One       Date:  2013-11-22       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.